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Alzheimer disease (AD) is a chronic degenerative dis-
order of the brain, which accounts for the most common
form of dementia in the elderly. During the past decade,
much effort has been devoted to the delineation of mech-
anisms of this disease and to the search for new treat-
ment strategies. The histopathology of AD is well es-
tablished, with hallmarks including senile plaque
(complex protein aggregates containing the b-amyloid
peptide [Ab]), neuritic tangles (remnants of neurons con-
taining hyperphosphorylated t protein), loss of neurons,
damaged synaptic connections, and reactive gliosis. Re-
active gliosis involves both microglia, which attack the
senile plaque (fig. 1), and astroglia, which surround the
plaque complex as a protective wrap.
Views concerning the pathogenesis of dementia have
evolved significantly during the past few years. It is gen-
erally agreed that abnormalities of Ab metabolism are
critical for the development of AD (Selkoe 1993). Epi-
demiology, coupled with biochemical studies, has iden-
tified mutations within Ab-precursor protein (APP) as
causal factors for familial forms of AD, whereas iso-
forms of apolipoprotein E (apo E) have been identified
as risk factors for sporadic disease (Selkoe 1993; Stritt-
matter et al. 1993; Price et al. 1998; Growdon 1999).
Moreover, intracellular aspects of dementia have re-
ceived much attention, since abnormalities in presenilin
appear to affect processing of APP and production of
Ab (Kovacs and Tanzi 1998; Sisodia et al. 1999 [in this
issue]). Regardless of initiating events for the disease, it
is recognized that neuronal and synaptic damages are
responsible for loss of cognitive function in AD. What
remain uncertain are the events that link Ab metabolism
with loss of neurons. Many disease pathways contrib-
uting to AD pathology have been proposed; the role of
the brain immune cell, the microglia, is considered here.
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Microglia—Immune Cells of the CNS
Microglia are a discrete population of phagocytes that
first appear as colonies of embryonic brain and that mi-
grate throughout the CNS, becoming distributed among
white and gray matter. Precursor cells take on amoeboid
shapes during development and differentiate into qui-
escent, ramified forms; this maturation is complete by
the time of birth. Quiescent cells found in mature brain
(Giulian 1987) act as sentinels to protect neural tissues
during injury and disease. Various signals associated
with disease—such as bacterial-wall components, tissue
debris, and viral-coat proteins—induce quiescent mi-
croglia to become reactive (Giulian 1992). Signaling
molecules, such as the colony-stimulating factorsM-CSF
and GM-CSF, appear to help the recruitment of reactive
microglia to sites of insult by promoting cell migration
and proliferation (Giulian and Ingeman 1988).
Using bone-marrow–chimera models to track cell mi-
gration, Hickey and Kitamura (1988) found that blood
monocytes do not enter the CNS to replace microglia.
The lack of exchange between mononuclear cells gen-
erated outside the brain and those within the brain is
also supported by cell-culture data (Giulian et al. 1995b)
that show monocytes and microglia to be quite different
in their proliferative capacities, their responses to cy-
tokines, and their patterns of morphological differenti-
ation. Thus, in culture and in situ, microglia ramify long,
thin processes hundreds of microns in length; these struc-
tures are not found in blood monocytes or in macro-
phages derived from tissues other than the CNS. Second,
scanning-electron microscopy shows a thick coat of
spines over the surface and projections of microglia but
not on other classes of mononuclear phagocytes (Giulian
et al. 1995b). Third, microglia, unlike all other phago-
cytic cells, rapidly enter a quiescent state—defined by
low expression of surface receptors, minimal secretory
activity, and minimal migratory behavior—when they
are in contact with astroglia and neurons. This quiescent
state accounts for the immune privilege associated with
the CNS; it is the transformation from the quiescent to
the reactive state that reveals the essence of AD immune
pathology.
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Figure 1 Photomicrographs of brain section showing thioflavin-
stained senile plaque (A) that is undergoing attack by a clustered group
of reactive microglia stained for HLA-Dr antigen (B). (Bar 
)20 microns
Neurotoxic Microglia, Dementia, and AD
Bolsi’s first description (1927) of argentophilic reac-
tive microglia near plaques in AD brain has been con-
firmed by use of many other markers that are char-
acteristic of this cell type, including the class
II–histocompatibility antigen HLA-DR (McGeer et al.
1987) and the class A scavenger receptors (Christie et
al. 1996). Early investigators were not certain whether
activation of glia in AD contributed to the disease pro-
cess or merely reflected ongoing pathology. A growing
body of information argues for the latter model, since
microglia have been recognized as the immune-effector
cell of the brain. For example, reactive microglia occur
within amyloid deposits that are associated with tissue
injury and dementia—the neuritic and core plaques—but
not within diffuse plaques, which are considered clini-
cally benign Ab deposits (Perlmutter et al. 1992; Giulian
et al. 1995a). Such selectivity in the distribution of re-
active glia suggests that specific signals within neuritic
and core plaques drive brain inflammation. The pattern
into which reactive microglia distribute themselves in
AD (fig. 1) is unique to this disease and suggests an
important role for brain inflammatory responses in its
etiology.
It is generally believed that destruction of neurons and
synapses ultimately accounts for the functional decline
of AD patients. Plaques may serve as stable irritants that
hold the CNS in a chronic state of inflammation, pro-
moting the activation and recruitment of microglia.
These cells, in turn, influence the course of cell death,
by secreting neurotoxins. Support of this hypothesis
comes from models in vitro. Plaque fragments are en-
gulfed within minutes when placed in cultures of human
microglia (Giulian et al. 1995a). In terms of morphology,
these cells change from quiescent, ramified forms to re-
active, amoeboid shapes, as seen in reactive microglia
surrounding plaques in situ (Giulian et al. 1995a). Cru-
cially, plaque-activated—but not quiescent—microglia
secrete neuron-killing factors. Plaque fragments do not
show direct toxic effects on neuron cultures depleted of
microglia, indicating that immune cells of the brain are
necessary to mediate plaque injury to neurons.
Additional lines of evidence support the likelihood
that reactive microglia are a source of brain neurotoxins.
For example, neurotoxins that can be extracted from
specific regions of AD brain (mid-frontal, parietal, and
occipital lobes; cerebellum; hippocampus; and subcor-
tical white matter) are not found either in amyotrophic
lateral sclerosis (ALS) or in normal, elderly control
brains. Regional distribution of this toxic activity shows
the greatest concentrations of microglia-derived neuron
poisons in either neocortical tissues and hippocampi of
AD brains (vs. control or ALS brains) or those areas
containing large numbers of reactive microglia. In con-
trast, AD cerebellum, AD white matter, and neocortical
tissues from normal or ALS patients, which have few
reactive microglial clusters, show little neurotoxic activ-
ity. The relative number of reactive microglial clusters
in each brain region is significantly correlated to that
region’s level of neurotoxic activity. Tissue injury in AD
may depend, therefore, on the magnitude of microglial
response to senile plaques and not simply on plaque
density.
Cellular Events That Direct Microglia during
Alzheimer Disease
Current research efforts to determine specific events
that drive microglia to damage AD brain have focused
on the identification of immune signals within plaques,
cell-surface receptors for plaque recognition, and neu-
rotoxic pathways. Gel filtration of solubilized plaque
components shows that only those fractions containing
Ab peptides induce neurotoxic microglia (Giulian et al.
1996). Confirmation that Ab peptides are activators of
microglia comes from the fact that synthetic forms of
full-length human Ab 1-42 promote neuron killing. As
in the case of native plaques, high concentrations of Ab
1-40 or Ab 1-42 do not damage neurons unless microglia
are present.
Although the synthetic forms of human Ab 1-40 and
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Figure 2 A, Plaque recognition by quiescent microglia, representing the first step of the activation cascade. The principal activating signals
found within the aggregate of plaque proteins are forms of Ab 1-42 that contain the cell recognition domain HHQK. The Ab receptor linked
to microglial neurotoxicity is a membrane protein in close association with cell-surface heparan sulfate. B, Strategies to suppress the immu-
nopathology of AD. Small peptides that compete with the HHQK binding site on microglia offer one way to prevent microglia-plaque interactions
(Giulian et al. 1998). A number of anti-inflammatory drugs might also serve as microglial suppressants, by preventing transformation into
reactive cells or by blocking such relevant functions as secretion; cell-culture studies suggest that chloroquine is one such agent (Giulian 1998).
A third possibility for hindering of immune-mediated damage involves blockade of cytotoxic agents released by plaque-activated microglia
(Giulian et al. 1995a). The most prominent toxic factors recovered thus far from neuron-killing microglia and AD brain are lipophilic amines.
NMDA-receptor antagonists prevent these compounds from damaging neurons in vitro and in vivo (Giulian et al. 1995a).
Ab 1-42 are also potent stimuli for neurotoxic microglia,
rodent Ab 1-40 is not (Giulian et al. 1998). Since the
only differences between the human and rodent peptides
are found at residues 5, 10, and 13 (5ArgrGly;
10TyrrPhe; 13HisrArg), the N-terminal portion of hu-
man Ab must contain some primary structure necessary
to stimulate microglia. Chemical modifications of Arg5
or of Tyr10 within human Ab 1-42 had no effect on
activation of microglia, suggesting that neither of these
residues is essential for cell stimulation. On the other
hand, residues His13, His14, Gln15, and Lys16, which
define the HHQK domain within Ab, are required for
induction of neurotoxic microglia. This tetrapeptide,
which is believed to exist on the hydrophilic surface of
Ab fibrils, seems to mediate Ab attachment to microglia.
Thus, the binding of Ab 1-42–coupled microspheres to
microglia is fivefold greater than that of control mi-
crospheres (Giulian et al. 1996). N-terminal peptides
from this domain of the protein, such as Ab 1-28, also
promote cell binding, whereas the C-terminal portion,
Ab 17-42, does not. Moreover, microglial binding to Ab
1-42–coupled microspheres can be blocked by coincu-
bation with peptides containing the HHQK domain, but
not by peptides from elsewhere in the protein (Giulian
et al. 1998). These data suggest that HHQK participates
in plaque induction of neuron killing, by providing, on
Ab, a recognition site for microglial binding (fig. 2A).
Several laboratories are pursuing receptors that link
Ab-complex formation with cell-surface receptors and
microglial reactions in AD. Increased expression of scav-
enger receptors is characteristic of reactive microglia
(Giulian 1992) and has been noted in AD brain samples
as well (Christie et al. 1996). These receptors bind spe-
cifically to a diverse collection of polyanionic molecules;
the high level of scavenger-receptor expression in mon-
onuclear phagocytes, including microglia, has led inves-
tigators to consider this class of surface molecule as a
mediator of immune response to injury. El Khoury et al.
(1996) and Paresce et al. (1996) both have reported an
uptake of synthetic Ab peptides involving scavenger-re-
ceptor pathways. However, competition studies do not
support direct binding of Ab 1-42 to scavenger receptor.
Moreover, microglia from Scav/ mice, which lack the
class A scavenger receptors, retain the ability to release
neurotoxins after Ab 1-42 exposure (D. Giulian and D.
Via; unpublished data).
Ab 1-42 binding to microglia is markedly reduced by
mild trypsinization of intact cells, suggesting involve-
ment of membrane-surface proteins. Both treatment of
cultured microglia with heparitinase and blockade of
glycosaminoglycans (GAGs) production, by addition of
b-D-xyloside, also reduce both Ab binding to microglia
and Ab-dependent induction of microglial neurotoxins.
Moreover, competition—either fromHHQK, for a bind-
ing site found within full length human Ab1-42, or from
soluble heparan sulfate GAG chains—inhibitsmicroglial
activation by plaques. Since basic HHQK also functions
as a charged site that binds to either acidic heparan
sulfate or heparan sulfate-containing GAGs (Giulian et
al. 1998), these observations suggest that some microg-
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Table 1
Putative Microglia-Derived Toxins and AD
Putative Toxin
Released
by Microglia
Cytotoxic
Status
Neurotoxic
Status
Presence
in AD Brain
Glutamine /  / 
Quinolinic acid    
Reactive oxygen species    
Nitric oxide    
TNFa    
Interleukin-1    
Lipophilic amines    
lial receptor for Ab peptides cooperates with plasma
membrane–bound heparan sulfate to initiate a neuron-
killing pathway (fig. 2A). Such participation of heparan
sulfate may help to explain other aspects of AD pa-
thogenesis. For example, apo E, a risk factor for AD, is
both secreted and sequestered by microglia. Since apo E
employs heparan sulfate as a docking site for cell bind-
ing, microglial interactions with apolipoproteins may al-
ter Ab induction of brain inflammation during the course
of AD.
The Search for Neurotoxins in AD
The increasing recognition that, through release of
cytotoxic factors, reactive microglia mediate neuronal
injury (Banati et al. 1993; Giulian et al. 1990; Giulian
et al. 1993) has prompted speculation that microglia-
derived complement proteins, cytokines, excitotoxins,
nitric oxide, reactive oxygen species (ROS), or lipophilic
amines (McGeer et al. 1990; Thery et al. 1991; Behl et
al. 1994; Giulian et al. 1995a; Meda et al. 1995; Mrak
et al. 1995) act as the proximate cause of neuronal death
in AD. Although a number of specific cytotoxic factors
are reported to participate in Ab-induced neurotoxicity,
it not clear that all of these putative neurotoxic agents
are actually produced in significant amounts by microg-
lia in AD brain or that they all act as neurotoxins in
situ (table 1). For example, after exposure to Ab, there
is no reduction of microglia-mediated neuron killing by
such potent inhibitors of nitric oxide synthetase as di-
phenyl iodonium or L-N-5-(1-imino-ethyl)-ornithine hy-
drochloride. Moreover, there is no evidence of increased
release of nitrites or nitrates (stable metabolites of nitric
oxide) or of the cytokines interleukin-1 or tumor-necro-
sis factor a (TNFa) by microglia after exposure to Ab
1-42. Speculation that TNFa is a neurotoxic agent is
not generally supported by either in vitro or in vivo
experimentation.
Novel toxic agents may also be released by Ab-acti-
vated microglia. My laboratory has partially character-
ized a microglia-derived fraction that is associated with
cytotoxic activity. The activity observed is of low mo-
lecular weight (!1 kD), heat stable, resistant to protein-
ases, and identical, in its chromatographic properties, to
AD brain–derived lipophilic amines (Giulian et al.
1995a, 1996). These compounds are very potent neu-
rotoxins, capable of destroying hippocampal neurons at
picomolar concentrations in vivo (Giulian et al. 1995a).
Their action is blocked by N-methyl-D-aspartate
(NMDA)–receptor antagonists. Such data support the
notion that NMDA receptor–bearing neurons are par-
ticularly vulnerable to immune attack in AD. Thus, of
the candidate microglia-derived toxins indicated in table
1, ROS and lipophilic amines appear to be the agents
most likely to cause the neuropathology seen in AD.
Immune Pathways as Targets for Dementia Therapies
Plaque-induced microglial attack on neurons offers a
number of targets for therapeutic intervention (fig. 2B).
These targets include (1) the signaling steps that reac-
tivate microglia in the presence of neuritic or core
plaques, (2) the synthesis and secretion of neurotoxins
by microglia, and (3) the effect that microglia-derived
toxins have on neurons. Since Ab 1-42 constitutes a ma-
jor component of the plaque, the interruption of Ab 1-
42 binding to microglia, perhaps by peptides that con-
tain the crucial HHQK sequence, may impede any
plaque induction of neuron killing (Giulian et al. 1998).
HHQK-like compounds offer the advantage that they
should suppress only the toxicity that occurs during Ab-
dependent activation, and they would not be predicted
to impair other immune functions (Giulian et al. 1998).
Mounting evidence that brain inflammation contrib-
utes to neuronal injury raises the hope that immuno-
suppressants could preserve memory and cognition in
the AD populations (McGeer et al. 1990). Several ret-
rospective studies have implicated anti-inflammatory
drugs as beneficial for AD, and treatment trials have
been suggested on the basis of these data (Breitner et al.
1990; Eikelenboom et al. 1994). However, many com-
monly used immunosuppressants (including glucocor-
ticoids) do not actually reduce neurotoxic activities of
microglia (Giulian 1992). Screening of immunosuppres-
sive drugs now used or under consideration for clinical
trials—including corticosteroids, indomethacin, colchi-
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cine, and chloroquine—have shown that only chloro-
quine is found to be effective against Ab-induced neu-
rotoxicity in cultured microglia (Giulian 1998). Such
studies point to the need for more thoughtful preclinical
evaluation of current immunosuppressive strategies to
treat AD.
It may also be possible to exploit, for therapeutic pur-
poses, the role of NMDA receptors in the cell-killing
pathway. As noted above, both in vitro and in vivo stud-
ies suggest that NMDA-receptor antagonists protect
against from toxic agents released by Ab-activated mi-
croglia. Perhaps NMDA-receptor antagonists such as
memantine, remacemide, and dextromethor-
phan—which are now undergoing further study in clin-
ical trials for stroke, trauma, and epilepsy—may offer
benefit to the AD patient.
Future Directions
During the past several years, studies ofmicroglia have
implicated a wide range of immunomodulators, cell-sur-
face receptors, cytotoxic pathways, and cell migratory
behaviors in the etiology of AD. Reactive microglia are
also a source of proteinases that degrade plaques and,
thus, may affect both the life span of Ab deposits and
the rate of disease progression. Much effort has been
directed toward the development of transgenic models
(Price et al. 1998) in which disease variants of the human
amyloid-precursor protein are overexpressed in the brain
of the mouse. Such AD models display many of the neu-
ropathological hallmarks, including neuritic and core
plaques and reactive gliosis with clusters of reactive mi-
croglia. Further study of such transgenic models will
offer us the opportunity to examine initial microglial
interactions with newly forming plaques. Such models
may also provide an in vivo source of microglia-derived
neurotoxins elicited by Ab. And further probing may
uncover relationships between microglia and AD risk
factors. For example, manipulation of apo E and its
receptors may determine if heparan sulfate interactions
with Ab are altered by apolipoprotein docking on the
surface of microglia. Since microglia are both a source
and a target of cytokines, genetic variations of immu-
nomodulators may reflect changes in disease risk (Pa-
passotiropoulos et al. 1999).
Clustered populations of reactive microglia are hall-
marks of AD. These brain immune cells are likely to
contribute to the mechanisms of neuronal damage and
cognitive loss. Since microglial biology can lead both to
insights concerning pathways of neuron degeneration
and to identification of AD risk factors, research in this
area will doubtless accelerate identification of new drug
targets for treatment of dementia.
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